Managing virtual R&D organizations: Lessons from the pharmaceutical industry

International Journal of Technology Management

Volumn 13, Issue 5-6, 1997, Pages 471-485

  Chiesa, Vittorio ^a,c,d,e,f   Manzini, Raffaella ^a,b,d,g  

^a POLITECNICO DI MILANO   (Italy)

^b Libero Ist Univ C Cattaneo   (Italy)

^c CNR   (Italy)

^d CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

^f LONDON BUSINESS SCHOOL   (United Kingdom)

^g LIUC   (Italy)

Author keywords

R D; Research networks; Strategic alliances; Virtual organization; Virtual R D

Indexed keywords

DRUG PRODUCTS PLANTS; INDUSTRIAL MANAGEMENT; INDUSTRIAL RESEARCH; STRATEGIC PLANNING;

STRATEGIC ALLIANCES; VIRTUAL RESEARCH AND DEVELOPMENT ORGANIZATIONS;

RESEARCH AND DEVELOPMENT MANAGEMENT;

EID: 0030648964     PISSN: 02675730     EISSN: None     Source Type: Journal    
DOI: 10.1504/ijtm.1997.001677     Document Type: Article

References (26)

1. Chesbrough, H. and Teece, D.J., (1996) 'When is virtual virtuous? Organizing for innovation', Harvard Business Review, January-February, pp.65-73.
2. Upton, D.M. and McAfee, A., (1996), 'The real virtual factory', Harvard Business Review, July-August.
3. Davidow, W.H. and Malone, M.S., (1992) The Virtual Corporation, Harper Business, New York.
4. Goold, M., Campbell, A. and Alexander, M., (1994) Corporate Level Strategy, John Wiley & Sons, Inc.
5. Albertini, S. and Butler, J., (1995) 'R&D networking in a pharmaceutical company: some implications for human resource management', R&D Management, vol. 25, n. 4, pp.377-393.
6. Arora, A., and Gambardella, A., (1994) The changing technology of technological change: general and abstract knowledge and the division of innovative labour', Research Policy, vol. 23, pp.523-532.
7. Della Valle F. and Gambardella, A. (1993), 'Biological' revolution and strategies for innovation in pharmaceutical companies', R&D Management, 23, 4.
8. Forrest, J. E., (1996) 'Japanese/US technological competitiveness and strategic alliances in the biotechnology industry', R&D Management, vol. 26, n. 2, pp.141-154.
9. Kodama, F., (1992), 'Technology fusion and the new R&D', Harvard Business Review, 70, 4, pp.70-78.
10. Perrino, A.C. and Tipping, J.W. (1989) 'Global management of technology', Research and Technology Management, 32, 3.
11. Prahalad, C.K., Doz, Y.L., (1987), The Multinational Mission: Balancing Local Demand and Global Vision, The Free Press, New York, N.Y., U.S.A.
12. Westney, D.E., (1990), 'Internal and external linkages in the MNC: The case of R&D subsidiaries in Japan', in Bartlett, C.A., Doz, Y., Hedlund, G., eds., Managing the Global Firm, Routledge, New York, USA.
13. Quinn J.B. and Hilmer, F.G., (1994) 'Strategic outsourcing', Sloane Management Review, Summer, pp.43-55.
14. Venkatesan, R., (1992) 'Strategic sourcing: to make or not to make', Harvard Business Review, November-December.
15. Forrest, J.E. and Martin, M.J.C, (1992) 'Strategic alliances between large and small research intensive organizations: experiences in the biotechnology industry', R&D Management, vol. 22, n. 1, pp.41-53.
16. PhRMA, (1993) Statistical Data.
17. Drews J., (1992) 'Pharmaceutical industry in transition', Drug News and Perspectives, vol. 5, n.3, pp.133-138.
18. Drews J., (1989), 'Research in the pharmaceutical industry', European Management Journal, 7, pp.23-30.
19. Henderson, R., (1994) 'Managing innovation in the information age', Harvard Business Review, January-February.
20. Chiesa, V., (1996) 'Separating reserach from development: evidence from the pharmaceutical industry', European Management Journal vol. 14, n. 6.
21. Chatterje, D., (1996) 'Accessing external sources of technology', Research & Technology Management, March-April, pp.48-56.
22. Chiesa, V. and Manzini, R., (1996) 'Profiting from the virtual organization of innovation: suggestions from an empirical study' Paper presented at the 6th International Forum on Technology Management, 15-17 October, Amsterdam.
23. Doz, Y. L., (1996) 'The evolution of cooperation in strategic alliances: initial conditions or learning processes?', Strategic Management Journal, vol. 17, pp.55-83.
24. The collaborations in the discovery phase mostly involve research centres and universities. Firm-to-firm collaborations often involve small and large firms. Small firms show advantages in this phase because of their flexibility and informal organization, whereas they are often weak in downstream phases of the process where the investments required are much higher. Therefore, a large firm may be interested in funding a research in a small firm and buy the result of it. Firm-to-firm collaborations usually occur when research methods are concerned. Usually there are few leading firms skilled in the use of a certain research approach. For example Affymax is the leading company in combinatorial chemistry, which is the basic discipline for the high throughput screening approach.
25. This definition is borrowed from the Dictionary of Clinical Research, Brookwood.
26. Fitzgerald, J.D., (1992) 'Technology transfer issues in licensing pharmaceutical products', R&D Management, 22, 3.